◆英語タイトル:Repros Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3479
◆発行会社(調査会社):
GlobalData
◆発行日:2018年8月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Repros Therapeutics Inc (Repros), formerly Zonagen Inc, a subsidiary of Allergan PLC, is a biopharmaceutical company that develops and markets drugs to treat hormonal and reproductive system disorders. The company’s pipeline product includes enclomiphene and proellex. Its enclomiphene is an orally active proprietary small molecule compound for men of reproductive age with low testosterone due to secondary hypogonadism. The company’s proellex is a chemical entity that acts as a selective blocker of the progesterone receptor and is used for the treatment of symptoms associated with uterine fibroids and endometriosis. Repros is headquartered in Houston, Texas, the US.
Repros Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Repros Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Repros Therapeutics Plans to Raise Funds through Public Offering of Shares and Warrants 10
Repros Therapeutics Prices Public Offering of Shares and Warrants for USD3 Million 11
Repros Therapeutics Raises USD2.9 Million in Private Placement of Shares 12
Repros Therapeutics Completes Public Offering Of Shares For US$82 Million 13
Repros Therapeutics Raises USD24 Million in Private Placement Of Shares 15
Repros Therapeutics Completes Private Placement Of Shares For US$11.1 Million 16
Acquisition 17
Allergan to Acquire Repros Therapeutics in Tender Offer 17
Repros Therapeutics Inc – Key Competitors 19
Repros Therapeutics Inc – Key Employees 20
Repros Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Nov 13, 2017: Repros Therapeutics Reports Third Quarter 2017 Financial Results 22
Aug 14, 2017: Repros Therapeutics Reports Second Quarter 2017 Financial Results 24
May 09, 2017: Repros Therapeutics Reports First Quarter 2017 Financial Results 26
Mar 31, 2017: Repros Therapeutics Reports Fourth Quarter and Year End 2016 Financial Results 27
Corporate Communications 28
Apr 10, 2017: Repros Names Larry Dillaha, M.D., its Permanent President and CEO 28
Feb 02, 2017: Repros Announces New CEO 29
Product News 30
12/15/2017: Repros Therapeutics Receives Feedback Following an Oral Explanation with the European Medicines Agency 30
01/26/2018: Repros Announces Negative Opinion From the EMA for Enclomiphene 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32
List of Tables
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Repros Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Repros Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Repros Therapeutics Plans to Raise Funds through Public Offering of Shares and Warrants 10
Repros Therapeutics Prices Public Offering of Shares and Warrants for USD3 Million 11
Repros Therapeutics Raises USD2.9 Million in Private Placement of Shares 12
Repros Therapeutics Completes Public Offering Of Shares For US$82 Million 13
Repros Therapeutics Raises USD24 Million in Private Placement Of Shares 15
Repros Therapeutics Completes Private Placement Of Shares For US$11.1 Million 16
Allergan to Acquire Repros Therapeutics in Tender Offer 17
Repros Therapeutics Inc, Key Competitors 19
Repros Therapeutics Inc, Key Employees 20
List of Figures
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Repros Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8